Steroid Hormone Receptors in the Central Nervous System

Author(s):  
Ivan Lieberburg ◽  
Bruce S. McEwen
1983 ◽  
Vol 5 (2) ◽  
pp. 185-192 ◽  
Author(s):  
Daniel P. Cardinali ◽  
María I. Vacas ◽  
Mónica N. Ritta ◽  
Pablo V. Gejman

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1168
Author(s):  
Deokho Lee ◽  
Yohei Tomita ◽  
William Allen ◽  
Kazuo Tsubota ◽  
Kazuno Negishi ◽  
...  

The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors and modulators of cellular metabolism. In this regard, PPARs have recently been suggested as promising therapeutic targets for suppressing the development of CNS diseases and their progressions. While the therapeutic role of PPARγ modulation in CNS diseases has been well reviewed, the role of PPARα modulation in these diseases has not been comprehensively summarized. The current review focuses on the therapeutic roles of PPARα modulation in CNS diseases, including those affecting the brain, spinal cord, and eye, with recent advances. Our review will enable more comprehensive therapeutic approaches to modulate PPARα for the prevention of and protection from various CNS diseases.


Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3408
Author(s):  
Giulia Scotto ◽  
Fulvio Borella ◽  
Margherita Turinetto ◽  
Valentina Tuninetti ◽  
Anna A. Valsecchi ◽  
...  

Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most women experience relapses. In most cases, recurrence is abdominal-pelvic; however, EOC can occasionally metastasize to distant organs, including the central nervous system. The incidence of brain metastases (BMs) from EOC is low, but it has grown over time; currently, there are no follow-up strategies available. In the last decade, a few biomarkers able to predict the risk of developing BMs from OC or as potential therapeutic targets have been investigated by several authors; to date, none have entered clinical practice. The purpose of this review is to offer a summary on the role of the most relevant predictors of central nervous system (CNS) involvement (hormone receptors; BRCA; MRD1; PD-1/PD-L1) and to highlight possible therapeutic strategies for the management of metastatic brain disease in EOC


Sign in / Sign up

Export Citation Format

Share Document